文献速递神经肿瘤小儿神经外科与脑积水

Sturgeon 如何在小儿神经肿瘤外科中指导术者

How 'Sturgeon' guides the surgeon in pediatric neuro-oncology.
PubMed 文献 · Neuro Oncol · 2026-08-10

该研究在荷兰 Princess Máxima 儿童肿瘤中心将术中冰冻切片与 Sturgeon 超快速纳米孔测序联合用于儿童原发性中枢神经系统肿瘤的手术决策。94 例连续患者中 Sturgeon 在 90 分钟内给出正确诊断 82 例(87.2%),支持原定手术策略 85.7%、改变策略 14.3%,并减少二次手术、促进早期告知。

要点

  • Sturgeon 可在 90 分钟内提供甲基化诊断,正确率 87.2%。
  • 术中诊断支持原策略 85.7%,改变策略 14.3%。
  • 应用与低并发症、较少二次手术及更早沟通相关。

核心结论

  • 术中 Sturgeon 为儿童中枢神经系统肿瘤提供关键指导,有助于选择更优手术策略并可能改善临床结局。

研究设计与样本

  • 荷兰 Princess Máxima 儿童肿瘤中心自 2023 年 5 月起将术中冰冻切片联合 Sturgeon 纳米孔测序作为标准诊疗流程。
  • 该流程适用于所有小于 19 岁、经多学科讨论需行肿瘤切除手术的原发性中枢神经系统肿瘤患儿。

主要发现

  • 94 例连续患者中 Sturgeon 在 90 分钟内给出正确诊断 82 例(87.2%)。
  • 11.7% 未获得诊断,1.1% 为错误诊断。
  • Sturgeon 诊断支持原定手术策略 85.7%,改变策略 14.3%(更积极或更局限切除)。
  • 该流程与低并发症率、较少二次手术及更早向患者家庭沟通组织分子诊断相关。

临床怎么用

  • 对需手术切除的儿童原发性中枢神经系统肿瘤,可在术中联合冰冻切片与 Sturgeon 纳米孔测序辅助实时决策。
  • 依据术中分子诊断可调整切除范围,并向家属更早沟通诊断信息。

局限性

  • 原文指出其他纳米孔测序策略虽已有描述,但明确临床影响证据仍严重缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Central nervous system (CNS) tumors represent the leading cause of pediatric cancer-related deaths. Primary treatment often involves neurosurgical tumor resection. Accurate diagnosis is crucial to perform the best-suited extent of resection. Recently, we published Sturgeon, an AI-based validated intraoperative nanopore sequencing tool, delivering accurate methylation-based diagnoses during surgery. Although several other nanopore sequencing strategies have been described, clear evidence of clinical impact remains critically absent. Here, we report a care evaluation analyzing the impact of Sturgeon on real-time pediatric neurosurgical decision-making. METHODS: Since May 2023, a dual diagnostic neuro-oncological workflow incorporating intraoperative frozen section analyses and ultra-fast nanopore sequencing using Sturgeon has been fully implemented as standard of care at the Princess Máxima Center for Pediatric Oncology in the Netherlands. This intraoperative diagnostic workflow has been applied to all pediatric patients (<19 years of age) with primary CNS tumors and the multidisciplinary indication for tumor resection surgery. RESULTS: Sturgeon delivered correct diagnoses in 82 out of 94 consecutive patients (87.2%, <90 minutes), no diagnosis in 11.7% and one incorrect diagnosis (1.1%). The diagnosis obtained by Sturgeon supported the intended surgical strategy (85.7%) or changed the strategy (14.3%) toward a more aggressive or limited resection. This contributed to a low complication rate and less second-look surgeries. Earlier communication of the histomolecular diagnosis to patients and their families was observed. CONCLUSIONS: Intraoperative use of Sturgeon provides essential guidance toward the most optimal neurosurgical strategy for pediatric CNS tumors and thereby has great potential to contribute to better clinical outcome. Brain and spinal cord tumors are the leading cause of cancer-related death in children. For most patients, surgical tumor removal is the first step in treatment. During surgery, doctors must quickly determine the tumor type to choose the safest and most effective amount of tumor to remove. We evaluated Sturgeon, a new sequencing-based diagnostic tool providing the tumor type during surgery. In most cases, Sturgeon supported the planned surgical approach, while in others it led to a meaningful strategy change. Its use was associated with fewer repeat-surgeries and earlier communication of results to families, potentially improving patient care and outcomes.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sie M, Eelkman Rooda OHJ, Kranendonk MEG, et al. How 'Sturgeon' guides the surgeon in pediatric neuro-oncology. Neuro Oncol. 2026. PMID: 42576322. doi:10.1093/neuonc/noag187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。